Fidaxomicin more cost effective than vancomycin in patients with cancer infected with clostridium difficile
the ONA take:
According to new research presented at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2014), patients with cancer who become infected with clostridium dificile would save about €5,600 per patient if treated with fidaxomicin compared with vancomycin, the current standard of care.
Clostridium dificile infection (CDI) can often present in patients received chemotherapy. In addition, those with solid cancers can be more susceptible to CDI than those with liquid tumors due to longer hospital admissions and increased antibiotic exposure and anti-cancer agents. When antibiotics alter a patient's gut flora and destroy many bacteria that live in the gut, clostridium dificile is given the chance to multiply and cause infection, thus causing diarrhea requiring antibiotics with gram-positive anaerobic coverage.
The most common agents used to treat CDI are metronidazole, oral vancomycin, and fidaxomicin, but treatment depends on severity of the infection. Multiple courses of oral vancomycin can be expensive for patients, and this decision-tree analysis demonstrates that fidaxomicin for the treatment of CDI in patients with cancer can reduce healthcare spending while maintaining effectiveness compared with vancomycin.
Those infected with clostridium dificile would save about €5,600 per patient if treated with fidaxomicin.
New data presented at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2014) show that overall treatment costs for cancer patients with clostridium difficile infection (CDI), based on a decision tree analysis, are lower with fidaxomicin compared to current standard of care, vancomycin, resulting in a potential cost saving of €5,600 per patient.
Patients who have received chemotherapy and those with solid tumours can be particularly susceptible to CDI due to their long hospital stays and exposure to many antibiotics and chemotherapeutic agents. These patients are also prone to recurrent episodes of CDI.
Sign Up for Free e-newsletters
- Education May Better Equip Nurses to Hold End-of-Life Conversations in Advanced Cancer
- Avoiding the ED: Planned Strategies for Unplanned Urgent Cancer Care
- NP-Led Clinics Improved Phase 1 Oncology Study Operations, Outcomes
- Accurate Understanding of Capacity May Improve Workflow, Efficiency in Infusion Suite
- Art as Palliative Care: Bedside Intervention Improves Pain, Anxiety, Mood in Hospitalized Cancer Patients
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|